Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment. Issue 10 (17th February 2021)

• Record Type: Journal Article
• Authors: Xu, Zhe; Arnold, Matthew; Stevens, David; Kaptoge, Stephen; Pennells, Lisa; Sweeting, Michael J; Barrett, Jessica; Di Angelantonio, Emanuele; Wood, Angela M
• Is Part Of: American journal of epidemiology. Volume 190:Issue 10(2021)
• Page Start: 2000
• Page End: 2014
• Publication Date: 2021-02-17
• Subjects: cardiovascular disease -- electronic health records -- future statin initiation -- longitudinal data -- risk prediction -- treatment drop-in; Epidemiology -- Periodicals; Public health -- Periodicals; 614.4
• DOI: 10.1093/aje/kwab031
• Languages: English
• ISSNs: 0002-9262

Abstract

Abstract: Cardiovascular disease (CVD) risk-prediction models are used to identify high-risk individuals and guide statin initiation. However, these models are usually derived from individuals who might initiate statins during follow-up. We present a simple approach to address statin initiation to predict "statin-naive" CVD risk. We analyzed primary care data (2004–2017) from the UK Clinical Practice Research Datalink for 1, 678, 727 individuals (aged 40–85 years) without CVD or statin treatment history at study entry. We derived age- and sex-specific prediction models including conventional risk factors and a time-dependent effect of statin initiation constrained to 25% risk reduction (from trial results). We compared predictive performance and measures of public-health impact (e.g., number needed to screen to prevent 1 event) against models ignoring statin initiation. During a median follow-up of 8.9 years, 103, 163 individuals developed CVD. In models accounting for (versus ignoring) statin initiation, 10-year CVD risk predictions were slightly higher; predictive performance was moderately improved. However, few individuals were reclassified to a high-risk threshold, resulting in negligible improvements in number needed to screen to prevent 1 event. In conclusion, incorporating statin effects from trial results into risk-prediction models enables statin-naive CVD risk estimation and provides moderate gains in predictive ability but had a limited impact on treatment decision-making under current guidelines in this population.